Cardinal Health has been selected as a distributor for Telix Pharmaceuticals' Gozellix®, an important development for the company, particularly in the U.S. market. Over the last quarter, Cardinal Health's stock moved 2%, a performance slightly better than the broader market's decline amid market volatility and tariff concerns. The company's partnership with Telix, combined with strategic board appointments of healthcare and tech experts, might have offered some resilience against broader market pressures. The cash dividend reaffirmation and share repurchase updates likely further bolstered investor confidence in otherwise turbulent market conditions.

Cardinal Health has 1 risk we think you should know about.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Cardinal Health's recent selection as a distributor for Telix Pharmaceuticals' Gozellix® could positively affect the company's trajectory, supporting the narrative of expanding key therapeutic offerings through strategic partnerships. Over a five-year period, Cardinal Health's total shareholder return was 183.89%, reflecting substantial growth. This performance aligns with the strategy outlined, despite short-term challenges due to integration costs and changing trade policies.

In the more recent one-year period, Cardinal Health's returns outpaced the broader US market, which experienced a 3.8% decline. This outperformance may highlight investor confidence in the company’s ability to leverage strategic acquisitions and focus on higher-margin business areas.

The news regarding the Gozellix® distribution could influence revenue and earnings forecasts positively, enhancing existing growth expectations. Analysts project revenue growth of 6.6% annually for the next three years, with earnings reaching US$1.9 billion by April 2028. Such partnerships potentially support these forecasts, reinforcing the company’s growth initiatives.

Regarding the current market valuation, Cardinal Health's share price stands at US$137.13, slightly below the consensus analyst price target of US$141.87, only 3.3% higher. This marginal difference suggests that the market may view the stock as fairly valued, underscoring the importance of investor sentiment in light of recent developments.

The analysis detailed in our Cardinal Health valuation report hints at an deflated share price compared to its estimated value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:CAH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com